Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,183

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Open access
Mas, Jean-Louis, Derumeaux, Geneviève, Guillon, Benoît, Massardier, Evelyne, Hosseini, Hassan, Mechtouff, Laura, Arquizan, Caroline, Béjot, Yannick, Vuillier, Fabrice, Detante, Olivier, Guidoux, Céline, Canaple, Sandrine, Vaduva, Claudia, Dequatre-Ponchelle, Nelly, Sibon, Igor, Garnier, Pierre, Ferrier, Anna, Timsit, Serge, Robinet-Borgomano, Emmanuelle, Sablot, Denis, Lacour, Jean-Christophe, Zuber, Mathieu, Favrole, Pascal, Pinel, Jean-François, Apoil, Marion, Reiner, Peggy, Lefebvre, Catherine, Guérin, Patrice, Piot, Christophe, Rossi, Roland, Dubois-Randé, Jean-Luc, Eicher, Jean-Christophe, Meneveau, Nicolas, Lusson, Jean-René, Bertrand, Bernard, Schleich, Jean-Marc, Godart, François, Thambo, Jean-Benoit, Leborgne, Laurent, Michel, Patrik, Pierard, Luc, Turc, Guillaume, Barthelet, Martine, Charles-Nelson, Anaïs, Weimar, Christian, Moulin, Thierry, Juliard, Jean-Michel, Chatellier, Gilles·2017·New England Journal of Medicine

Abstract

BACKGROUND: Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy. METHODS: In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3. RESULTS: A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P<0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P=0.02). The number of serious adverse events did not differ significantly between the treatment groups (P=0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone. CONCLUSIONS: Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1705915

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 1,183

Metadata

Authors
Mas, J.-L., Derumeaux, G., Guillon, B., Massardier, E., Hosseini, H., Mechtouff, L., Arquizan, C., Béjot, Y., Vuillier, F., Detante, O., Guidoux, C., Canaple, S., Vaduva, C., Dequatre-Ponchelle, N., Sibon, I., Garnier, P., Ferrier, A., Timsit, S., Robinet-Borgomano, E., Sablot, D., Lacour, J.-C., Zuber, M., Favrole, P., Pinel, J.-F., Apoil, M., Reiner, P., Lefebvre, C., Guérin, P., Piot, C., Rossi, R., Dubois-Randé, J.-L., Eicher, J.-C., Meneveau, N., Lusson, J.-R., Bertrand, B., Schleich, J.-M., Godart, F., Thambo, J.-B., Leborgne, L., Michel, P., Pierard, L., Turc, G., Barthelet, M., Charles-Nelson, A., Weimar, C., Moulin, T., Juliard, J.-M., & Chatellier, G.
Venue
New England Journal of Medicine
Published
2017-09-14
Volume
377
Issue
11
Pages
1011-1021
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2755636520
Cited by
1,183
References
24
FWCI
102.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. https://app.cochat.ai/papers/10.1056/nejmoa1705915
The paper
Mas, J.-L., Derumeaux, G., Guillon, B., Massardier, E., Hosseini, H., Mechtouff, L., Arquizan, C., Béjot, Y., Vuillier, F., Detante, O., Guidoux, C., Canaple, S., Vaduva, C., Dequatre-Ponchelle, N., Sibon, I., Garnier, P., Ferrier, A., Timsit, S., Robinet-Borgomano, E., . . . Chatellier, G. (2017). Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1705915

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.